Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XERECEPT Extended-Use in Peritumoral Brain Edema
NCT00226655Phase 3Completed
- Sponsor
- Celtic Pharma
- Start
- Jul 2005
- Primary completion
- Mar 2009
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of corticorelin ovine triflutate in cerebral edema, sponsored by Celtic Pharma. Primary endpoint: Long Term Safety and Tolerability of hCRF. Started Jul 2005; status: completed.
02
Drugs
corticorelin ovine triflutate
03
Conditions
cerebral edema
Beyond the preview
Go deeper on NCT00226655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00226655.